Healthcare Economist February 2, 2025
Jason Shafrin

Some hints–and only hints–were provided in a CMS press release on Wednesday.

Lowering the cost of prescription drugs for Americans is a top priority of President Trump and his Administration. In accordance with the statutory requirements of the Inflation Reduction Act, the Centers for Medicare and Medicaid Services (CMS) released the list of 15 drugs selected for the second cycle of the Medicare Drug Price Negotiation Program on January 17, 2025. As the second cycle begins under the Trump Administration, CMS is committed to incorporating lessons learned to date from the program and to considering opportunities to bring greater transparency in the Negotiation Program. CMS intends to provide opportunities for stakeholders to provide specific ideas to improve the Negotiation...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, CMS, Congress / White House, Govt Agencies, Insurance, Medicare, Pharma, Pharma / Biotech
CMS issues Stark law guidance for physician-owned hospital
An Argument For A New Medicare Prospective Payment System Methodology For Certified Community Behavioral Health Clinics
What's going on with physician pay?
The Cost of Eliminating the Enhanced Premium Tax Credits
Rewarding Medicare Advantage D-SNPs That Provide The Best Value

Share This Article